<DOC>
	<DOC>NCT01489488</DOC>
	<brief_summary>Primary objective: To determine oral bioavailability of the liquid formulation intended for pediatric use and potential food effects in healthy adults. Secondary objective: To evaluate safety and tolerability measured by physical examination findings, vital signs, electrocardiogram (ECG), laboratory parameters, and adverse events (AEs).</brief_summary>
	<brief_title>Relative Bioavailability and Food Effect Study</brief_title>
	<detailed_description>Clinical pharmacology</detailed_description>
	<criteria>Healthy male or female volunteers Age 1845 years Body mass index (BMI) 18.029.9 kg/mÂ² Systolic blood pressure (SBP) 110145 mmHg No drugs 2 weeks before treatment Nonsmokers for at least 12 weeks Incompletely cured preexisting diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal Medical disorder that would impair the subject's ability to complete the study in the opinion of the Investigator Known hypersensitivity to the study drugs (active substance or excipients of the preparations) Known severe allergies, nonallergic drug reactions, or multiple drug allergies Relevant diseases within the last 4 weeks prior to the first study drug administration Regular use of medicines Regular use of therapeutic or recreational drugs Use of any medication within the 2 weeks preceding the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Relative bioavailability study</keyword>
</DOC>